Literature DB >> 1525845

Bone densitometry measurements in early inflammatory disease.

A K Bhalla, B Shenstone.   

Abstract

Entities:  

Mesh:

Year:  1992        PMID: 1525845     DOI: 10.1016/s0950-3579(05)80182-7

Source DB:  PubMed          Journal:  Baillieres Clin Rheumatol        ISSN: 0950-3579


× No keyword cloud information.
  7 in total

1.  Association of 1.25 vitamin D3 deficiency, disease activity and low bone mass in ankylosing spondylitis.

Authors:  U Lange; J Teichmann; J Strunk; U Müller-Ladner; K L Schmidt
Journal:  Osteoporos Int       Date:  2005-09-20       Impact factor: 4.507

2.  Assessing periarticular bone mineral density in patients with early psoriatic arthritis or rheumatoid arthritis.

Authors:  B J Harrison; C E Hutchinson; J Adams; I N Bruce; A L Herrick
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

3.  Ankylosing spondylitis and bone mineral density--what is the ideal tool for measurement?

Authors:  Uwe Lange; A Kluge; J Strunk; J Teichmann; G Bachmann
Journal:  Rheumatol Int       Date:  2004-11-05       Impact factor: 2.631

4.  Measurement of hand bone mineral content by dual energy x-ray absorptiometry: development of the method, and its application in normal volunteers and in patients with rheumatoid arthritis.

Authors:  A A Deodhar; J Brabyn; P W Jones; M J Davis; A D Woolf
Journal:  Ann Rheum Dis       Date:  1994-10       Impact factor: 19.103

5.  Antibodies to human tissue transglutaminase and alterations of vitamin D metabolism in ankylosing spondylitis and psoriatic arthritis.

Authors:  Joachim Teichmann; Marcus J Voglau; Uwe Lange
Journal:  Rheumatol Int       Date:  2009-10-13       Impact factor: 2.631

6.  Prevalence of metacarpal osteopenia in young rheumatoid arthritis patients.

Authors:  A A Kalla; O L Meyers; R Laubscher
Journal:  Clin Rheumatol       Date:  1995-11       Impact factor: 2.980

Review 7.  Osteoimmunology and osteoporosis.

Authors:  Piet Geusens; Willem F Lems
Journal:  Arthritis Res Ther       Date:  2011-09-30       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.